Clinical Trials - December 8, 2025
Aurealis Therapeutics announces positive Phase 2 results
The company has announced positive blinded evaluator efficacy results and completion of the Database Lock (DBL) in its DIAMEND Phase 2 clinical trial of AUP-16, the company’s lead asset for the treatment of non-healing neuro-ischemic Diabetic Foot Ulcers (DFUs).
Clinical Trials - November 26, 2025
First subject dosed in One-carbon Therapeutics study
The first subject has been dosed in the company's ODIN Phase 1/2 clinical trial evaluating TH9619, a first-in-class MTHFD1/2 inhibitor.
Clinical Trials - November 21, 2025
Evaxion announces positive data for lead antigens in CMV vaccine program
Evaxion is advancing its novel multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program.
Clinical Trials - November 13, 2025
Lytix Biopharma announces interim data on neoadjuvant treatment
Lytix Biopharma has announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.
Clinical Trials - November 11, 2025
Arctic Therapeutics receives EMA approval for Phase IIa study in Alzheimer’s
The company has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Clinical Trials - November 10, 2025
Lytix Biopharma announces new immune response data
The company has presented immune response data on ruxotemitide (formerly LTX-315/VP-315) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.
